Pfizer brands animal health spinoff "Zoetis"

Share this article:
Pfizer emerged from Q3 2013 with a 3% drop in earnings compared to the same period last year
Pfizer emerged from Q3 2013 with a 3% drop in earnings compared to the same period last year
Pfizer edged one step closer to divesting its animal health business. The company had previously said it intended to pare down the company's scope with two moves: to sell or spin off its nutrition business and to do the same with its animal health division. The first culminated in an $11.9 billion sale to Nestle, of candy bar fame.

The company announced Friday that a spin-off will take care of the second goal. The new company will be named Zoetis, which the company said means “pertaining to life.” Juan Ramon Alaix, president of Pfizer Animal Health, said in a statement that the name “best captures the company's focus on partnerships with veterinarians, livestock producers and companion animal owners."

The company said the business, which boasts more than 9,000 employees, pulled in sales of about $4.2 billion in 2011, and will continue to be included in Pfizer's financial reports until separation is final.

Friday's statement indicated that the company plans to hold an IPO for a limited number of shares and will lay out the offering's details when it presents is second-quarter results, with the goal of completing the spin-off by July 2013.

Although not a surprising, the Pfizer breakup is part of a trend that larger players have increasingly come to embrace. GlaxoSmithKline has been shedding businesses for quite some time and Abbott will spin off its biopharma division AbbVie by year's end. Goldman analyst Jami Rubin recently urged J&J to take a similar tack.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...